Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance

Cytokinetics IncTrade
Direxion NASDAQ 100 Equal Weighted Index SharesTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Cytokinetics Inc trades at $76.31 (market cap $10.63B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $123.18. The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.

CYTKQQQE
Market Cap
$10.63B
Sector
TechnologyBroad Market / Factor
52-Week High
$87.26$122.72
52-Week Low
$34.31$96.06
Enterprise Value
$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Direxion NASDAQ 100 Equal Weighted Index Shares

QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $123.01, up 0.7% today, with a bullish technical signal from moving averages. The fund provides diversified exposure to the Nasdaq-100 with equal weighting, reducing concentration risk compared to cap-weighted peers. Recent news highlights its appeal as a defensive play amid tech-led market rallies and the upcoming inclusion of SpaceX in the index.

The outlook remains positive given equal-weight diversification benefits and strong Nasdaq-100 growth trends. Key risks include market volatility and sector concentration, but analyst sentiment favors QQQE for balanced Nasdaq exposure. The ETF's structure mitigates single-stock risk while capturing broad large-cap growth.

Returns comparison

Trailing returns across standard periods

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Direxion NASDAQ 100 Equal Weighted Index Shares

QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.

Read more on QQQE